KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBT (2018 - 2025)

Vir Biotechnology's EBT history spans 8 years, with the latest figure at -$43.1 million for Q4 2025.

  • For Q4 2025, EBT rose 58.86% year-over-year to -$43.1 million; the TTM value through Dec 2025 reached -$437.8 million, up 16.31%, while the annual FY2025 figure was -$437.8 million, 16.31% up from the prior year.
  • EBT for Q4 2025 was -$43.1 million at Vir Biotechnology, up from -$163.0 million in the prior quarter.
  • Across five years, EBT topped out at $921.9 million in Q1 2022 and bottomed at -$233.7 million in Q2 2022.
  • The 5-year median for EBT is -$120.9 million (2023), against an average of -$14.3 million.
  • The largest YoY upside for EBT was 646.43% in 2022 against a maximum downside of 483.04% in 2022.
  • A 5-year view of EBT shows it stood at $545.9 million in 2021, then crashed by 127.78% to -$151.6 million in 2022, then rose by 20.36% to -$120.8 million in 2023, then grew by 13.32% to -$104.7 million in 2024, then skyrocketed by 58.86% to -$43.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's EBT are -$43.1 million (Q4 2025), -$163.0 million (Q3 2025), and -$110.8 million (Q2 2025).